A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune mediated neuropathy responding to immunomodulation with IVIG or plasma exchange (PE). We tested the efficacy and safety of selective immunoglobulin removal by Excorim immunoadsorption (IA) in a pilot trial in CIDP patients randomized to monthly IA or IVIG treatments for 6 months. Response rates at 2 and 6 months were greater with IA due to longer disease duration and greater disability at baseline in the patients receiving IVIG. IA appears to be a safe and efficacious therapy for patients with CIDP, but an appropriately powered clinical trial with stratification for disease duration is required.
Zinman
L H
LH
Toronto General Hospital, University Health Network, Eaton Wing, 11-209, 200 Elizabeth Street, Toronto, ON, Canada.
Sutton
D
D
Ng
E
E
Nwe
P
P
Ngo
M
M
Bril
V
V
D000293:Adolescent; D000328:Adult; D000368:Aged; D001426:Bacterial Proteins / Q000737:chemistry / Q000627:therapeutic use*; D003711:Demyelinating Diseases / Q000150:complications / Q000628:therapy*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D010951:Plasma Exchange / Q000379:methods; D011115:Polyneuropathies / Q000150:complications / Q000628:therapy*; D013210:Staphylococcus / Q000737:chemistry
D001426:Bacterial Proteins; D016756:Immunoglobulins, Intravenous